Search results for "Diuretic"

showing 10 items of 139 documents

Contemporary Management of Struvite Stones Using Combined Endourologic and Medical Treatment: Predictors of Unfavorable Clinical Outcome

2016

Struvite stones have been associated with significant morbidity and mortality, yet there has not been a report on the medical management of struvite stones in almost 20 years. We report on the contemporary outcomes of the surgical and medical management of struvite stones in a contemporary series.A retrospective review of patients who were treated with percutaneous nephrolithotomy (PCNL) for struvite stones at Duke University Medical Center between January 2005 and September 2012 identified a total of 75 patients. Of these, 43 patients had adequate follow-up and were included in this analysis. Stone activity, defined as either stone recurrence or stone-related events, and predictors of acti…

AdultMalemedicine.medical_specialtyStruviteUrologymedicine.medical_treatment030232 urology & nephrologyComorbidityHydroxamic AcidsKidney CalculiYoung Adult03 medical and health scienceschemistry.chemical_compoundPostoperative Complications0302 clinical medicineRecurrencePotassium CitratemedicineHumansUniversity medicalEnzyme InhibitorsDiureticsPercutaneous nephrolithotomyAgedNephrostomy PercutaneousRetrospective StudiesAged 80 and overRetrospective reviewMedical treatmentbusiness.industryChlorthalidoneRetrospective cohort studyMiddle Agedmedicine.diseaseComorbidityAnti-Bacterial AgentsSurgerySodium BicarbonateTreatment OutcomechemistryStruvite030220 oncology & carcinogenesisNephrostomyFemaleCalcium CitratebusinessJournal of Endourology
researchProduct

Tolerability and efficacy of high-dose furosemide and small-volume hypertonic saline solution in refractory congestive heart failure

2000

Thirty patients aged 65-85 years, with refractory New York Heart Association (NYHA) class IV congestive heart failure (CHF) were treated with an intravenous infusion of furosemide (250-2000 mg/d) and small-volume hypertonic saline solution (150 mL of 1.4-4.6% NaCl) twice a day for 6 to 12 days. A daily fluid oral intake of 1000 mL and previous cardiac therapy were maintained. Clinical signs and symptoms of CHF, such as dyspnea, edema and weakness, improved, as did severity of illness as defined by NYHA class. The infusion was well tolerated. After a 12-month follow-up, 24 patients (80%) were alive and in the NYHA class assigned on discharge from the hospital. This therapeutic combination is…

Aged 80 and overHeart FailureMaleSaline Solution HypertonicAged; Aged 80 and over; Diuretics; Female; Furosemide; Heart Failure; Humans; Infusions Intravenous; Italy; Male; Saline Solution Hypertonic; Statistics Nonparametric; Survival RateStatistics NonparametricSurvival RateItalyFurosemideDiureticHumansFemaleInfusions IntravenouDiureticsInfusions IntravenousHumanAged
researchProduct

Pharmacological heterogeneity of γ-aminobutyric acid receptors during development suggests distinct classes of rat cerebellar granule cells in situ

2001

The gamma-aminobutyric acid receptor (GABA(A)R) represents a ligand-gated Cl(-)-channel assembling as heteropentamere from 19 known subunits. Cerebellar granule cells contain a unique subset, namely the alpha1-, alpha6-, beta2-, gamma2- and delta-subunits. We studied their GABAergic pharmacology in situ using whole-cell patch-clamp recordings in brain slices and a modified Y-tube application system. The distribution of the EC50s for GABA in young (P8-P14) and medium aged animals (P15-P28) could be fitted with the sum of two Gaussian distributions with means of 60 and 185 microM and 27 and 214 microM, respectively. In older animals (P29-P48) the observed homogeneous range of sensitivities fi…

Agingmedicine.medical_specialtyCerebellumPatch-Clamp TechniquesLoreclezoleConvulsantsIn Vitro TechniquesBiologyBicucullineInhibitory postsynaptic potentialAminobutyric acidMembrane PotentialsGABA AntagonistsRats Sprague-DawleyCellular and Molecular Neurosciencechemistry.chemical_compoundFurosemideCerebellumInternal medicineDMCMmedicineAnimalsDiureticsGABA ModulatorsReceptorPharmacologyDiazepamLong-term potentiationReceptors GABA-ARatsElectrophysiologymedicine.anatomical_structureEndocrinologychemistryGABAergicAlgorithmsCarbolinesmedicine.drugNeuropharmacology
researchProduct

H-Point Curve Isolation Method for Coupled Liquid Chromatography and UV−Visible Spectrophotometry

2000

The H-point curve isolation method (HPCIM) for the detection of unknown interferences in chromatography is proposed. The method allows one to estimate the UV-vis spectra of interfering species in a sample as well as to test the purity of the chromatographic peaks. Besides the detection of the unknown interferences in a sample, this method allows one to calculate the concentration of an analyte in the presence of unknown compounds. To illustrate the reliability of the proposed method, samples of diuretics and amphetamines have been analyzed by normal- and reversed-phase high-performance chromatography.

AnalyteChromatographymedicine.diagnostic_testChemistryAmphetaminesAnalytical chemistryAnalytical ChemistryChromatography detectorSpectrophotometrymedicineSpectrophotometry UltravioletDiureticsChromatography columnChromatography LiquidAnalytical Chemistry
researchProduct

Generalised H-point standard addition method for the isolation of the analyte signal from the sample signal when coelution of unknown compounds occur…

1999

The generalised H-point standard addition method (GHPSAM) is proposed for isolating the analytical signal of an analyte from the signal of an unknown sample. Samples containing two and three coeluting compounds have been analysed. The accuracy of the predictions depends on the shape of the analyte and interferent spectra but not on the degree of chromatographic overlap. This methodology involves the location of linear intervals for the unknown interference spectrum from the spectrum of the sample. Once the linear interval has been found the selection of three wavelengths within the interval will allow the cancellation of the signal of the unknown interferent. The method has been applied to …

AnalyteInternal standardChromatographyChemistryOrganic ChemistryAmphetaminesAnalytical chemistryGeneral MedicineBiochemistrySample (graphics)SignalHigh-performance liquid chromatographyAnalytical ChemistryInterference (communication)PhenolsStandard additionSpectrophotometry UltravioletDiureticsQuantitative analysis (chemistry)Chromatography LiquidJournal of chromatography. A
researchProduct

Determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine by capillary electrophoresis using ultraviolet absorba…

2002

Abstract Two capillary electrophoresis methods have been developed for the direct determination of triamterene and its main metabolite hydroxytriamterene sulfate in human urine. Analytes were detected using conventional UV detection as well as laser-induced fluorescence (LIF) detection with an HeCd-laser operating at a wavelength of 325 nm. The results of both detection techniques were compared. Indeed, the limit of quantification was eightfold lower using LIF detection (50 ng/ml) in comparison to UV detection (400 ng/ml). As no interference due to endogenous urine compounds was observed, direct urine analysis was feasible. Analysis was very simple and fast—one run could be performed within…

AnalyteMetaboliteClinical BiochemistryUrineBiochemistryAnalytical Chemistrychemistry.chemical_compoundCapillary electrophoresismedicineHumansDiureticsLaser-induced fluorescenceDetection limitTriamtereneChromatographyChemistryLasersElectrophoresis CapillaryReproducibility of ResultsCell BiologyGeneral MedicineFluorescenceSpectrometry FluorescenceSpectrophotometry UltravioletTriamterenemedicine.drugJournal of Chromatography B
researchProduct

Hypertension treatment in patients with sleep apnea from the European Sleep Apnea Database (ESADA) cohort - towards precision medicine.

2022

We recruited 5,970 patients with hypertension with obstructive sleep apnea (OSA) on current antihypertensive treatment from the European Sleep Apnea Database (ESADA) cohort. The group was subdivided into those receiving monotherapy (n = 3,594) and those receiving dual combined therapy (n = 2,376). We studied how major OSA confounders like age, gender, and body mass index as well as the degree of sleep apnea modified office systolic and diastolic blood pressure. Beta-blockers alone or in combination with a diuretic were compared with other antihypertensive drug classes. Monotherapy with beta-blocker was associated with lower systolic blood pressure, particularly in non-obese middle-aged male…

Behavioral NeurosciencehypertensionCognitive Neurosciencediureticbeta-blockerobstructive sleep apnea.General MedicineSettore MED/10 - Malattie Dell'Apparato Respiratorioantihypertensive treatmentJournal of sleep researchREFERENCES
researchProduct

Chromatographic separation of chlorthalidone enantiomers using β-cyclodextrins as chiral additives

2000

Different beta-cyclodextrins have been tested as chiral additives in the mobile phase for the chromatographic analysis of chlorthalidone enantiomers in a C18 LiChrospher (125 x 4 mm I.D.) column. The effect on enantioresolution of different parameters was studied: composition of the mobile phase (percentage of organic solvent, type of buffer and pH), mobile phase flow-rate, and type and concentration of beta-cyclodextrin. A 25:75 mixture of methanol and 0.1 M phosphate buffer, pH 4, containing 2% triethylamine (v/v), and 12.5 mM beta-cyclodextrin, at a flow-rate of 0.8 ml/min, was found to be the best option for the resolution of chlorthalidone enantiomers. Under such conditions, linear cal…

Beta-Cyclodextrinschemistry.chemical_compoundSpectrophotometrymedicineHumansDiureticsTriethylaminechemistry.chemical_classificationDetection limitCyclodextrinsChromatographyCyclodextrinmedicine.diagnostic_testbeta-CyclodextrinsChlorthalidoneStereoisomerismGeneral ChemistrySolutionschemistrySolventsIndicators and ReagentsSpectrophotometry UltravioletChlorthalidoneMethanolEnantiomermedicine.drugJournal of Chromatography B: Biomedical Sciences and Applications
researchProduct

Synthesis of [11C]SSR149415 and preliminary imaging studies using positron emission tomography.

2010

Abstract SSR149415 was the first non-peptide vasopressin-(V1b) receptor antagonist reported. It has been used to probe the role of V1b receptors in animal models of depression, aggression, and stress-anxiety, and was progressed to clinical trials for the treatment of depression. Due to the interest in V1b receptors as a therapeutic target and the growing use of SSR149415 in preclinical research, we developed a method to label SSR145419 with carbon-11 and have studied its pharmacokinetics in non-human primates using positron emission tomography.

BiodistributionReceptors VasopressinIndolesPyrrolidinesmedicine.drug_classClinical BiochemistryPharmaceutical ScienceAnxietyBiochemistryPreclinical researchAnimal models of depressionDrug DiscoverymedicineAnimalsCarbon RadioisotopesReceptorMolecular Biologymedicine.diagnostic_testbusiness.industryChemistryDepressionOrganic ChemistryAntagonistReceptor antagonistClinical trialBiochemistryAnti-Anxiety AgentsPositron emission tomographyPositron-Emission TomographyMolecular MedicineNuclear medicinebusinessAntidiuretic Hormone Receptor AntagonistsPapioBioorganicmedicinal chemistry letters
researchProduct

Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone.

2014

Aim The efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, was evaluated in patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and pioglitazone. Methods In this randomized, double-blind, phase 3 study, patients (N = 342) received canagliflozin 100 or 300 mg during a 26-week, placebo-controlled, core period and a 26-week, active-controlled extension in which placebo-treated patients were switched to sitagliptin 100 mg. Efficacy comparisons for canagliflozin versus placebo at week 26 are reported, with no comparisons versus sitagliptin at week 52 (sitagliptin used to maintain double-blind and control for safety). Safety data ar…

Blood GlucoseMaleendocrine system diseasesEndocrinology Diabetes and Metabolismphase 3 studyBlood PressureType 2 diabetesPharmacologyEndocrinologyGlucosidesWeight lossCanagliflozinCandidiasisSGLT2 inhibitorMiddle AgedDiuretics OsmoticLipidsMetforminMetforminTreatment OutcomePyrazinesDrug Therapy CombinationFemaletype 2 diabetesmedicine.symptomSGLT2 InhibitorGenital Diseases Malemedicine.drugmedicine.medical_specialtyUrologyThiophenesDouble-Blind MethodWeight LossInternal MedicinemedicineHumansHypoglycemic AgentsCanagliflozinthiazolidinedionesPioglitazonebusiness.industrySitagliptin Phosphatenutritional and metabolic diseasesType 2 Diabetes MellitusOriginal ArticlesTriazolesmedicine.diseaseBlood pressureDiabetes Mellitus Type 2businessPioglitazoneGenital Diseases FemaleDiabetes, obesitymetabolism
researchProduct